NewswireToday - /newswire/ - Raleigh, NC, United States, 10/06/2011 - Bioptigen has created the commercial market’s deepest spectral domain optical coherence tomography (SDOCT) system for pre-clinical applications - Bioptigen.com.

The ophthalmic imaging device company, Bioptigen Inc., has been named a finalist in three categories of the 2011 NCTA 21 Awards.

The NCTA 21 Awards are recognized as North Carolina’s largest and most prestigious awards devoted to promoting and celebrating innovation and high-tech excellence throughout the state. The annual showcase honors 21 companies and individuals representing the best and brightest in technology and business, and demonstrating outstanding leadership and innovation.

Bioptigen has created the commercial market’s deepest spectral domain optical coherence tomography (SDOCT) system for pre-clinical applications. NCTA named Bioptigen a finalist in the following award categories: Most Innovative Technology Company, Private Company Excellence, and Small Technology Stage of Development.

“To be named a NCTA 21 Awards finalist alongside the finest of North Carolina’s growing and established firms is exciting for everyone at Bioptigen,” said Dr. Eric Buckland, president and CEO. “I am proud of our employees and the passion they pour every day into developing revolutionary technologies that offer the potential to change our understanding of eye disease and treatment.”

The North Carolina Technology Association (NCTA) is a not-for-profit, membership-driven trade organization that serves as the primary voice for the state’s growing information technology industry.

Bioptigen’s high-performance optical imaging technologies support researchers and clinicians in the study of eye pathologies. The company’s Envisu™ spectral domain ophthalmic imaging platform employs low-power incoherent light to generate high-resolution, depth-resolved images of ocular tissues. Envisu rapidly acquires and displays volumetric images suitable for real-time exploration of tissue physiology and pathology.

Deployed in nine of the top 10 ophthalmic research institutions in the country, Bioptigen’s innovations are covered by more than 60 patent applications, including 30 awarded patents. Researchers and clinicians have published more than 100 scientific articles supported by data acquired through the use of the company’s technologies.

Agency / Source: Sinclair & Co.

Availability: All Regions (Including Int'l)

Traffic Booster: [/] Quick Newswire Today Visibility Checker

Distribution / Indexing: [+]